ProCE Banner Activity

Focus on Molecular Testing for MET Exon 14–Skipping Mutations in Advanced NSCLC

Multimedia
Watch a roundtable by experts who offer insight on the role of METex14 mutations in NSCLC with a focus on optimal testing methods for METex14-skipping mutations.

Released: August 20, 2020

Expiration: August 19, 2021

No longer available for credit.

Share

Faculty

Solange Peters

Solange Peters, MD, PhD

Full Professor
Clinical Director,
Thoracic Oncology Research Program
Chair, Medical Oncology
Department of Oncology
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland

Alexis Cortot

Alexis Cortot, MD, PhD

Professor
Pneumologie et Oncologie Thoracique
CHR de Lille, Lille University
Lille, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by an independent grant from the Healthcare business of

Merck KGaA

Learning Objectives

  • Describe the rationale for METex14 as a targetable alteration in NSCLC
  • Evaluate the available testing platforms and use of tissue and plasma biopsies to assess METex14 in patients with NSCLC

Program Director Disclosure

Program Director

Solange Peters, MD, PhD

Full Professor
Clinical Director,
Thoracic Oncology Research Program
Chair, Medical Oncology
Department of Oncology
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland

Solange Peters, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Novartis, PharmaMar, Pfizer, Regeneron, Sanofi, Seattle Genetics, and Takeda and nonfinancial support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp and Dohme, Merck Serono, Novartis, Pfizer, and Sanofi.

Faculty Disclosure

Primary Author

Alexis Cortot, MD, PhD

Professor
Pneumologie et Oncologie Thoracique
CHR de Lille, Lille University
Lille, France

Alexis Cortot, MD, PhD has disclosed that he has received funds for research support from Merck Serono and Novartis and consulting fees and other financial or material support from AstraZeneca, Novartis, and Pfizer.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Marie N. Becker, PhD

Scientific Director

Marie N. Becker, PhD, has no relevant conflicts of interest to report.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.